Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
~$7B
P/E ratio
~31×
Div yield
~0.5%
Revenue (FY25)
~$1.22B
Rev. growth
+5%
Op margin (Protein Sci.)
~43%
Segments
2
Inst. ownership
~68%
In plain English
Bio-Techne is a 'picks-and-shovels' supplier to the bio-revolution: it makes the specialized proteins, antibodies, reagents and immunoassays that academic labs, biotech and pharma use to discover drugs — and the GMP-grade cytokines that go into cell-and-gene therapies. A string of acquisitions (Advanced Cell Diagnostics, Exosome Diagnostics, Asuragen, Lunaphore) added a fast-growing spatial-biology and molecular-diagnostics arm on top.
In simple terms
What Bio-Techne really sells
Bio-Techne is a 'picks-and-shovels' supplier to the bio-revolution: it makes the specialized proteins, antibodies, reagents and immunoassays that academic labs, biotech and pharma use to discover drugs — and the GMP-grade cytokines that go into cell-and-gene therapies. A string of acquisitions (Advanced Cell Diagnostics, Exosome Diagnostics, Asuragen, Lunaphore) added a fast-growing spatial-biology and molecular-diagnostics arm on top.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.